SP
ALXN

Sarasin & Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Sarasin & Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-33,210
Closed -$4.41M – 140
2013
Q4 		$4.41M Hold
33,210
– – 0.06% 97
2013
Q3 		$3.86M Sell
33,210
-25,890
-44% -$2.84M 0.06% 95
2013
Q2 		$5.45M Buy
+59,100
New +$5.7M 0.08% 85

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sarasin & Partners's ALXN Position: Q1 2014 in Review

Sarasin & Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2014, closing a stake of 33,210 shares — an estimated $4.41M sold.

Sarasin & Partners first reported a position in ALXN in Q2 2013 and held it in 3 quarters. The position peaked at $5.45M in Q2 2013. 504 funds tracked by Wall St. Rank hold ALXN as of Q1 2014.

  • Sarasin & Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Sarasin & Partners sold 33,210 Alexion Pharmaceuticals shares in Q1 2014, an estimated $4.41M.
  • Sarasin & Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Sarasin & Partners's Alexion Pharmaceuticals position peaked at $5.45M in Q2 2013.
  • 504 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2014.

Based on Sarasin & Partners's 13F filing for Q1 2014, filed 9 Apr 2014.